Yvonne Voges

Paul Ehrlich Str. 40
Frankfurt Am Main, HE 60596, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Correction: Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

Correction: Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

Journal: Cell death & disease

Published: June 02, 2026

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting.

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting.

Journal: Cancers

Published: March 20, 2020

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines.

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines.

Journal: Cancers

Published: January 27, 2020

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.

Journal: Cell death & disease

Published: June 13, 2016

ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.

ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.

Journal: Oncotarget

Published: February 19, 2016

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.

Journal: Scientific reports

Published: August 01, 2014

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Journal: Translational oncology

Published: August 08, 2013

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

Journal: Cell death & disease

Published: April 06, 2012

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

Journal: Cell death & disease

Published: December 16, 2011

Showing 1-9 of 9

Last Updated: 09/26/2026